Overview
Dr. Kevin Wiehe is the director of research, director of computational biology and co-director of the Quantitative Research Division at the Duke Human Vaccine Institute (DHVI). He has over 20 years of experience in the field of computational biology and has expertise in computational structural biology, computational genomics, and computational immunology.
For the past decade, he has applied his unique background to developing computational approaches for studying the B cell response in both the infection and vaccination settings. He has utilized his expertise in computational structural biology to structurally model and characterize HIV and influenza antibody recognition. Dr. Wiehe has utilized his expertise in computational genomics and computational immunology to develop software to analyze large scale next generation sequencing data of antibody repertoires as well as develop computational programs for estimating antibody mutation probabilities. Dr. Wiehe has shown that low probability antibody mutations can act as rate-limiting steps in the development of broadly neutralizing antibodies in HIV.
Through his PhD, postdoc work, and now his roles at DHVI, Dr. Wiehe always approaches the analysis and the scientific discovery process from a structural biology perspective. Supporting the Duke Center for HIV Structural Biology (DCHSB), Dr. Wiehe will conduct antibody sequence analysis for antibodies used in computational and molecular modeling analyses conducted.
Current Appointments & Affiliations
Recent Publications
A tumor-binding antibody with cross-reactivity to viral antigens.
Journal Article Cancer Immunol Immunother · February 26, 2025 BACKGROUND: We previously identified in non-small cell lung cancer (NSCLC) patients an autoantibody to complement factor H (CFH) that is associated with non-metastatic disease and longer time to progression in patients with stage I disease. A recombinant h ... Full text Link to item CiteAn engineered immunogen activates diverse HIV broadly neutralizing antibody precursors and promotes acquisition of improbable mutations.
Journal Article Sci Transl Med · January 8, 2025 Elicitation of HIV broadly neutralizing antibodies (bnAbs) by vaccination first requires the activation of diverse precursors, followed by successive boosts that guide these responses to enhanced breadth through the acquisition of somatic mutations. Becaus ... Full text Link to item CiteNeonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus Macaques.
Journal Article Nat Commun · November 27, 2024 The details of the pediatric immune system that supports induction of antibodies capable of neutralizing geographically-diverse or heterologous HIV-1 is currently unclear. Here we explore the pediatric immune environment in neonatal macaque undergoing Simi ... Full text Link to item CiteRecent Grants
Innovations in Functional B Cell Epitope Discovery
ResearchInvestigator · Awarded by National Institutes of Health · 2024 - 2029SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens
ResearchInvestigator · Awarded by National Institute of Allergy and Infectious Diseases · 2022 - 2027DMS/NIGMS 1: Challenges in Stochastic Modeling and Computation for Sequential Vaccine Design
ResearchCo-Principal Investigator · Awarded by National Science Foundation · 2024 - 2027View All Grants